Insmed Incorporated (INSM) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

20/25

Growth 5 Margin 5 Expansion 5 Platform 3 Financial 2

latest quarter score

Earnings Reports

20
Insmed (INSM) Q2 2026: Peak Sales Outlook Jumps 75% as Brensupra Demand Surges
August 06, 2026
19
Insmed (INSM) Q1 2026: Brinsupri Delivers 44% Sequential Growth, Underpinning Long-Term Expansion
May 08, 2026
20
INSM Q4 2025: Brensupri Launch Drives $1B+ 2026 Guide, Unlocking Bronchiectasis Market Expansion
February 24, 2026
14
Insmed (INSM) Q3 2025: Brinsupri Launch Drives $28M in Six Weeks, Setting Up Multi-Asset Growth Cycle
October 30, 2025
14
Insmed (INSM) Q2 2025: $823M Capital Raise Powers Brenzocatib Launch and Pipeline Acceleration
August 07, 2025
13
Insmed (INSM) Q1 2025: 50% International Growth Sets Stage for Brenzocatib Launch
July 06, 2025

Browse all companies